Theranos Pitch Deck Teardown: A Case Study in High-Margin

Introduction and Title

Slide 1: Title Slide

The deck opens with a minimalist title slide dated June 1, 2006. It features the original Theranos logo, which incorporates a caduceus-style 'T'. The subtitle is simply 'A Presentation For Investors.' The background uses a blue digital-style banner at the top and bottom, suggesting a focus on informatics and data technology rather than just biology.

The Team and Governance

Slide 4: Management and Board of Directors

This slide is arguably the most important in the early Theranos narrative. It lists a management team with deep roots in established Silicon Valley and pharmaceutical companies. Elizabeth Holmes is listed as President and CEO, noting she left Stanford Chemical and Electrical Engineering to found the company. The supporting cast is high-profile: Howard Bailey (CFO) is credited with taking QED and Photon Dynamics public and serving as a Controller at Intel. Diane Parks (CCO) came from Genentech and Aventis. John Howard (Senior VP, Products) is a former President of Panasonic Semiconductor and IBM Microelectronics. Dr. Ian Gibbons is noted as the Senior Director of Assay Development with experience at Syva and Biotrack. The Board of Directors includes Donald L. Lucas , a 46-year VC veteran, and Channing Robertson , the Stanford Senior Associate Dean of Engineering. This slide aims to provide massive institutional credibility to offset the founder's lack of a degree or prior executive experience.

The System Architecture

Slide 7: Theranos ABCS™

Slide 7 introduces the 'Ambulatory BioInformatics Communications System.' The diagram shows a closed-loop ecosystem. A 'Home' unit with telecommunications and videoconferencing capabilities connects to 'Theranos Informatics' (represented by a large server rack). This data is then shared with 'Partners,' 'HMOs,' and 'Pharmacies.' The stated goal is 'Effective narrow range therapy through post-prescription monitoring of the total available patient base.' This positioning frames Theranos not as a lab company, but as a distributed informatics company that uses hardware as a data collection point.

Clinical Application and Toxicity Monitoring

Slide 10: Infusion Chemotherapy Monitoring

This slide provides a specific clinical use case: chemotherapy. It shows a graph where the 'First course drug level' (pink line) rises significantly above the 'Drug level target' (red line) to a 'toxic level' because the patient is not eliminating the drug rapidly. The slide argues that standard dose rates are insufficient without the real-time monitoring Theranos provides.

Slide 13: Real-time PK/PD Monitoring

Building on the previous slide, slide 13 shows a 'Scenario' where toxicity is observed, and the dosage is subsequently reduced to an acceptable level. The graph tracks five parameters: Drug Dose, Drug Level, Effect Marker, Toxicity Marker, and Tox. Alert Level. The x-axis spans 50 days, implying that the Theranos system is intended for long-term, chronic, or multi-week monitoring in a home or ambulatory setting, rather than just a one-off diagnostic test.

Business Model and Value Proposition

Slide 16: Theranos Value Proposition

This slide outlines the financial logic of the business. The revenue is derived from an 'Information fee' that includes the use of readers, cartridges, and the ABCS informatics platform. Key claims include:

70% margins : A very high projection for a hardware-reliant business. · Requisite solution : Positioned as a way for pharma companies to improve drug labels or preempt liabilities. · 20-30% cost savings : Claiming to be significantly cheaper for pharmaceutical companies than testing through a traditional clinician's office.

Strategic Advantages

Slide 19: Drivers for Success

Theranos lists its competitive moats here. It claims a 'First mover advantage' and asserts that the 'Combination of several different technologies makes reproducing the solution difficult.' It also mentions an 'Innovation Pipeline,' a 'Strong Customer Base' (though no specific customers are named on this slide), 'Patents,' and 'Management and Culture.' This is a standard 'why we win' slide, emphasizing the difficulty of replication.

Technical Validation

Slide 22: Technology: Theranos System versus Today's Lab

The final slide in this selection attempts to provide scientific proof. It features five charts comparing Theranos assays to conventional assays. The headline claim is that 'On chip Chemiluminescence enables greater sensitivity than the clinical lab.' The graphs show high correlation (R² values are visible but small) between the Theranos system and standard laboratory equipment. This slide is intended to silence doubts about the miniaturization of the technology by showing it performs at or above the level of full-scale lab machines.

What Works and What is Missing

What Works: The deck is highly effective at leveraging 'social proof' through its management slide. By 2006, having executives from Intel, IBM, and Genentech on a single slide for a startup was a significant achievement. The focus on the pharmaceutical industry (PK/PD monitoring) is also a smart strategic choice, as pharma companies have higher budgets and a greater need for real-time data than general practitioners. The 'Information Fee' model is a classic 'razor and blade' strategy but rebranded as a modern SaaS-style recurring fee, which would appeal to VCs looking for high margins.

What is Missing: The provided slides lack a clear 'Ask' (how much money is being raised and at what valuation). There is no detailed breakdown of the 'Strong Customer Base' mentioned on slide 19; without names of pharma partners, this remains a vague claim. Furthermore, while the deck mentions 'Patents,' it does not list patent numbers or specific intellectual property filings. The financial projections are limited to a margin percentage (70%) without a multi-year P&L or a clear path to profitability. Finally, there is no mention of FDA regulatory hurdles, which are a primary risk factor for any medical diagnostic device.

Founder Takeaways

The Power of the Team Slide: If you are a young founder, your team slide is your most important asset. Theranos successfully used the resumes of its executives to mask the lack of a finished, proven product. Focus on a High-Value Niche: Instead of trying to replace all blood tests at once, the deck focuses on high-stakes pharmaceutical monitoring (chemotherapy, toxicity). This makes the 'value proposition' much easier to defend. Bundle Hardware into Service: By calling their revenue an 'Information Fee' rather than 'Hardware Sales,' they reframed the business as a high-margin data play. Founders should consider how they frame their revenue to align with the multiples investors give to different industries (e.g., SaaS vs. Manufacturing).